Q-omics provides the consensus-scored TRAJ28 profile across patient tissues and cancer cell-line models. TRAJ28 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TRAJ28 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, TRAJ28 RNA expression shows 11,872 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, STAD, and LSCC as cancer lineages where TRAJ28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ28 survival associations across molecular data types. TRAJ28 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ28 RNA expression–survival associations across cancer types. High TRAJ28 expression shows unfavorable associations in LUSC, DLBC and READ, but favorable associations in HNSC, KIRC and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for TRAJ28 RNA expression.
This table summarizes TRAJ28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ28 shows lower tumor expression in THCA and higher tumor expression in STAD and KICH. The STAD box plot shows higher TRAJ28 RNA expression in tumor versus normal tissue (log2 FC = +0.407, t-test p = .017).
This table shows molecular features associated with TRAJ28 in patient tissues and cancer cell lines. In patient samples, TRAJ28 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
